Pfizer Reports Positive Results of Lyrica Study

The study enrolled 501 subjects and demonstrated a reduction in endpoint mean pain score compared to a placebo.

Pharma giant Pfizer recently announced positive top-line results from a Phase III study of Lyrica (pregabalin) as a treatment of fibromyalgia.

The 16-week, randomised, double-blind, multicentre and placebo-controlled A0081208 study enrolled 501 subjects. The drug demonstrated a reduction in endpoint mean pain score compared to a placebo.

The drug-related adverse events include drowsiness, dizziness, weight increase, constipation, oedema peripheral and blurred vision.